创模生物科技(北京)有限公司

CN / En

NEWS

In vivo tumor experimental platform of InnoModels Biotechnology: Detailed explanation of features and advantages

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-29 16:08
  • Views:

(Summary description)In the vast field of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is gradually becoming a leader in the field of cancer research and treatment with its innovative in vivo tumor experimental platform. With its unique technical advantages and comprehensive service system, this platform provides researchers with unprecedented experimental conditions and tools, greatly promoting the progress of cancer medicine.

In vivo tumor experimental platform of InnoModels Biotechnology: Detailed explanation of features and advantages

(Summary description)In the vast field of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is gradually becoming a leader in the field of cancer research and treatment with its innovative in vivo tumor experimental platform. With its unique technical advantages and comprehensive service system, this platform provides researchers with unprecedented experimental conditions and tools, greatly promoting the progress of cancer medicine.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-29 16:08
  • Views:
Information

In the vast field of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is gradually becoming a leader in the field of cancer research and treatment with its innovative in vivo tumor experimental platform. With its unique technical advantages and comprehensive service system, this platform provides researchers with unprecedented experimental conditions and tools, greatly promoting the progress of cancer medicine.
1. Advanced technology, simulated reality
The core advantage of the innovative in vivo tumor experimental platform is that it can highly simulate the tumor environment in the human body. The platform not only covers tumor models of multiple cancer types (such as breast cancer, lung cancer, gastrointestinal tumors, etc.), but also simulates complex physiological factors such as the immune system and blood supply to make experimental results closer to clinical reality. This highly simulated experimental environment provides researchers with a more accurate platform to evaluate drug effects and treatment options.
2. Diverse models and rich choices
The Innovation Biotechnology platform has a large tumor cell line library, covering more than 400 different tumor cell lines, covering a wide range of cancer types and subtypes. This diverse model selection allows researchers to choose the most suitable model for experiments based on their own research needs. Whether it is basic scientific research or preclinical drug evaluation, this platform can provide strong support.
3. Technological innovation to improve efficiency
Based on the team’s rich practical experience in PDX (human tumor xenograft) model modeling and experiments, InnoModels Biotechnology has successfully developed the second-generation iPDX model platform. This innovative technology not only greatly improves the modeling success rate and experimental stability, but also more completely retains the heterogeneity and genomic information of tumor tissues, making the consistency between drug efficacy response and clinical clinical results more than 90%. In addition, the iPDX model platform also has performance close to that of tumor cell line models, and can be used for large-scale experiments with early algebraic models, thus improving research efficiency and data reliability.

 


4. Strict quality control and reliable results
InnoModels Biotechnology is well aware of the importance of quality control for experimental results, so it has established a strict quality control system. During the modeling process, the platform ensures the accuracy and reliability of the model through multiple methods such as pathogenic microorganism detection, STR detection, and pathology detection. At the same time, the platform also maintains thorough and traceable experimental records to meet the needs of reporting and documentation standards. These measures provide researchers with strong data support and ensure the accuracy and credibility of experimental results.
5. Comprehensive services and support for personalization
The In Vivo Tumor Experimental Platform not only provides advanced experimental technologies and tools, but is also committed to providing comprehensive service support. The platform focuses on the fields of tumor and tumor immunopharmacodynamics CRO services, translational medicine research services and personalized medicine, and provides a new generation of experimental animal models that are close to clinical practice for new drug R&D companies, translational medicine researchers and tumor patients. In addition, the platform supports personalized treatment studies, allowing researchers to conduct experiments using patient tumor samples to better understand how different patients respond to specific treatment regimens.

6. Looking to the future and continuing to innovate
InnoModels Biotechnology is well aware that in the rapidly developing field of biomedical research, continuous innovation is the key to maintaining competitiveness. Therefore, the company plans to continuously expand model types, optimize experimental processes, and combine advanced technical means to provide researchers with more comprehensive and efficient services. In the future, InnoModels Biotechnology will continue to be committed to improving the technical level of in vivo tumor experimental platforms to respond to changing scientific research needs and promote the further development of cancer medicine.
To sum up, with its advanced technology, rich model selection, strict quality control and comprehensive service support, the in vivo tumor experimental platform of InnoModels Biotechnology has demonstrated strong competitiveness and broad development in the field of cancer research and treatment. prospect. With the continuous advancement of technology and the continuous optimization of services, this platform will surely bring breakthrough research results and clinical application value to more researchers.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司